Explore another way you may receive treatment.

Potential OPDIVO® (nivolumab) user eating cotton candy with his wife.
Potential OPDIVO® (nivolumab) user eating cotton candy with his wife.

Clinical trial results for
early-stage non-small
cell lung cancer
(NSCLC) before surgery

Given before surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery

Actor portrayals.

An FDA-approved combination of immunotherapy and chemotherapy that helped reduce the risk of cancer spreading or returning compared to platinum-based chemotherapy

Your doctor has determined having surgery will be an important step for you to take in treating your early-stage non-small cell lung cancer, but to make sure the tumor is small enough to be removed and that no hidden or hard to see cells are left, your doctor may recommend a pre-surgery treatment.

About the clinical trial

In a clinical trial of 358 people with early-stage NSCLC who were able to have surgery, 179 people were given OPDIVO + chemotherapy before surgery, and 179 people were given platinum-based chemotherapy before surgery.

People given OPDIVO + chemotherapy before surgery remained free of their cancer spreading or returning longer compared to platinum-based chemotherapy

At 32 months, half of those receiving OPDIVO® (nivolumab) + chemotherapy remained free of cancer spreading or returning.
OPDIVO + chemotherapy

Half the people remained free of cancer spreading or returning

At 21 months, half the people given platinum-based chemotherapy remained free of cancer spreading or returning.
Platinum-based chemotherapy

Half the people remained free of cancer spreading or returning

OPDIVO + chemotherapy given before surgery was proven to reduce the risk of their cancer spreading or returning by 37% compared to chemotherapy alone.

More people given OPDIVO + chemotherapy before surgery saw their tumors disappear completely after surgery compared to platinum-based chemotherapy

24% of patients given OPDIVO® (nivolumab) + chemo before surgery saw tumors disappear post-op, compared to 2% with just chemo.

OPDIVO + chemotherapy will not work for everyone. Individual results may vary.

OPDIVO Qvantig may be a faster* way to receive treatment.

It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.

Timer icon indicating the injection of OPDIVO® QVANTIG™ takes 3-5 minutes.
Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.

Getting treatment

See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)

For adults with early-stage non-small cell lung cancer (NSCLC) before surgery

As an intravenous infusion

OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early-stage lung cancer (called non-small cell lung cancer).

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.

As a subcutaneous injection

OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early-stage lung cancer (called non-small cell lung cancer).

It is not known if OPDIVO Qvantig is safe and effective in children.



466-US-2500008  03/25